REVIEW

Understanding diverse TRPV1 signaling – an update [version 1; peer review: 4 approved]

Michael C. Andresen

Department of Physiology and Pharmacology, Oregon Health & Science University, Portland, OR, 97239, USA

V1 First published: 25 Nov 2019, 8(F1000 Faculty Rev):1978
<https://doi.org/10.12688/f1000research.20795.1>

Latest published: 25 Nov 2019, 8(F1000 Faculty Rev):1978
<https://doi.org/10.12688/f1000research.20795.1>

Abstract

The transient receptor potential vanilloid 1 (TRPV1) is densely expressed in spinal sensory neurons as well as in cranial sensory neurons, including their central terminal endings. Recent work in the less familiar cranial sensory neurons, despite their many similarities with spinal sensory neurons, suggest that TRPV1 acts as a calcium channel to release a discrete population of synaptic vesicles. The modular and independent regulation of release offers new questions about nanodomain organization of release and selective actions of G protein-coupled receptors.

Keywords

TRPV1, NTS, solitary tract nucleus, synaptic transmission, vagus, cranial nerve, visceral afferent

Open Peer Review

Approval Status

	1	2	3	4
version 1 25 Nov 2019

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **David D Kline**, University of Missouri, Columbia, USA
2. **Tamara Rosenbaum**, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Coyoacan, México City, Mexico
3. **Renato Alberto Travagli**, Penn State - College of Medicine, Hershey, USA
4. **Andrei V Derbenev**, Tulane University, New Orleans, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Michael C. Andresen (andresen.ohsu@gmail.com)

Author roles: Andresen MC: Conceptualization

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by grants from the National Institutes of Health, HL-133505 (MCA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung and Blood Institute or the NIH.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Andresen MC. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Andresen MC. **Understanding diverse TRPV1 signaling – an update [version 1; peer review: 4 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1978 <https://doi.org/10.12688/f1000research.20795.1>

First published: 25 Nov 2019, 8(F1000 Faculty Rev):1978 <https://doi.org/10.12688/f1000research.20795.1>

That burning sensation in our mouth and throat on tasting a piquant food containing capsaicin introduces us to the transient receptor potential vanilloid 1 (TRPV1). This burning sensation relies on activation of TRPV1 channels expressed in local primary sensory neurons and, when that message arrives in the cortex, it is perceived as irritation or pain. Capsaicin has had a long culinary and experimental history, but the cloning of TRPV1 defined a major breakthrough by shifting the focus to its mechanism of action¹. TRPV1 is a homotetrameric membrane protein combining a transmembrane pore with domains devoted to vanilloid, thermal, and proton stimuli—each capable of triggering channel gating². This single protein provides integral, polymodal transduction via ion channel activation. Discovery of TRPV1 gave structure and focus to a varied and often confusing experimentation history with natural substances such as capsaicin, which showed a mix of response activation with response inhibition^{3,4} plus a rich cultural history reaching to pre-Columbian times⁵. TRPV1 has come to be intimately linked to pain and the molecular basis of nociceptor signaling⁶. TRPV1 activates a subset of slowly conducting thinly myelinated and unmyelinated somatosensory primary afferent neurons of the dorsal root ganglia (DRG) of the spinal cord. Our task here will be to briefly outline some of the major characteristics of TRPV1 activation established largely in DRG neurons and contrast these with recent developments in an entirely different set of TRPV1-expressing sensory afferents embedded deep within the body. In this article, I will focus on TRPV1 as a sensory transduction molecule and emphasize recent complementary work that suggests several new aspects of TRPV1 signaling in non-somatosensory primary afferents linked to innocuous neural functions.

Key attributes of TRPV1

The first key intrinsic properties of TRPV1 as an ion channel to appreciate are inseparable: calcium and depolarization. The strong calcium preference means that TRPV1 essentially serves as a calcium channel. TRPV1 conducts nearly 10-fold more calcium ions than other cations, so that measures of intracellular calcium levels often substitute as a metric for TRPV1 activity¹. However, the inward current flow depolarizes and recruits voltage-activated channels exciting the neurons. A second important aspect of TRPV1 is gating, where three distinct stimuli are represented in separate sequences within the TRPV1 structure^{7,8}. The three stimuli presumably produce conformation changes to the TRPV1 protein, resulting in gating the channel open, namely vanilloid binding to one site, protons binding to an additional acidic site, and raised temperature critically changing a third site^{9–12}. Remarkably, these three distinct stimuli gate open TRPV1 channels singularly but can act cooperatively in combination to facilitate gating so that threshold temperatures are lower in the presence of vanilloid—a property of this single protein which makes it a multimodal integrator^{13,14}. Singly, however, the minimum gating stimuli are notable for their extreme, supraphysiological intensities even at threshold: high temperature (>42 °C), low pH (~6), and vanilloid ligands such as capsaicin, a substance foreign to the mammalian body^{15,16}. Physiologically, such stimulus levels are reached only under extraordinary circumstances most often associated with frank tissue damage. The high affinity of plant-derived substances for

TRPV1 such as capsaicin and the picomolar affinity resiniferatoxin (RTX) raised the question of whether these compounds mimic endogenous vanilloid substances in vertebrate animals and humans^{17,18}. Certainly, on the basis of comparative chemical similarities, vanilloid moieties have been suggested as endogenous agonists (endovanilloids) to TRPV1^{19,20}. The complex interrelationship of anandamide and arachidonate metabolites and their highly varied fates offers a wide range of agonistic possibilities as well as uncertainties in the natural context^{21–23}. These properties of TRPV1 gating, ion selectivity, and modulation were remarkably conserved across a wide variety of experimental contexts, including heterologous expression systems such as transfected HEK293 cells and dispersed cultured DRG neurons to brain slices and *in vivo*. A third aspect of TRPV1 is the loss of responsiveness with continued activation. Prolonged or repeated exposure to high agonist concentrations substantially desensitizes TRPV1 function and depends on calcium entry and dephosphorylation^{24–26}. In the extreme with neonatal animals, TRPV1 agonists selectively kill TRPV1-expressing sensory neurons likely due to calcium overload, whereas in adult animals, such treatments deplete neurotransmitter and damage primary sensory neurons reducing or eliminating function^{3,27}. Intrathecal RTX produced analgesia as well as increases in blood pressure and heart rate²⁸. TRPV1 expression makes central axons vulnerable to damage by intrathecal RTX²⁹. Desensitization and competitive antagonism were exploited in attempts to design effective clinical analgesics³⁰. Whereas preclinical results were promising, the trial results were confounded by hyperthermia. Selective TRPV1 antagonists triggered a perplexing rise in body temperature largely through what appears to be block of a tonically activated peripheral TRPV1 site and this side effect curtailed clinical deployment as an analgesic³¹. Note that these trials focused solely on addressing somatosensory nociceptors but simultaneous visceral afferent contributions to temperature regulation foiled these efforts. This remains a controversial topic and TRPV1 vagal afferents are implicated³².

TRPV1 in the broader context of primary afferents

The link between TRPV1 and nociception is clear and compelling. What often is overlooked is the presence of TRPV1⁺ non-somatosensory neurons. Extensive work links capsaicin with subpopulations of somatosensory afferents with slower-conducting axons (A δ and C) beyond DRG neurons^{3,6}. Peripheral TRPV1 and capsaicin actions extend to unmyelinated cranial viscerosensory neurons to activate neural pathways controlling innocuous but vital functions like gastrointestinal control³³, blood pressure^{34,35}, and respiratory control³⁶. TRPV1 activation strongly excites cranial visceral afferents and activates pathways not involved in conscious perception but rather more in reflex alteration of autonomic functions, for example. These actions of capsaicin were described initially over 50 years ago³ but depended on the activation of specific subsets of visceral or interoceptive sensory neurons that included strong cardiorespiratory^{37,38} and thermoregulatory³⁹ responses.

Immunostaining and blots revealed dense staining for TRPV1 in nodose ganglion but extended into the brainstem at the nucleus of the solitary tract (NTS) and implicated TRPV1 in vagal primary afferents and their central transmission in the TRPV1-expressing

cohort of primary afferents⁴⁰. Interestingly, activation of these vagal central pathways inhibits nociceptive reflexes; that is, they are anti-nociceptive in consequence⁴¹. The frequency and intensity response profiles for vagal nerve stimulation are consistent with C-fiber activation and inhibited dorsal horn nociceptive responses; thus, craniovisceral C-fiber activation inhibits the somatosensory nociceptive process in the spinal cord⁴². Clearly, as both cranial and somatosensory afferents express TRPV1, this fact represents potential confounders in pain therapeutic strategies using vanilloid-based drugs. The relatively protected internal locations of visceral afferent TRPV1 limits heat and acid deviations to those compatible with life and thus are unlikely to reach canonical threshold levels in normal tissue. Such constraints raise interesting questions about the adequate stimulus for visceral and central TRPV1 endogenous activation.

Localization of TRPV1⁺ neurons

Early tritiated RTX binding assays identified extensive central structures, some directly linked to primary sensory afferents but others not (olfactory nuclei, the cerebral cortex, dentate gyrus, thalamus, hypothalamus, periaqueductal grey, superior colliculus, locus coeruleus, and cerebellar cortex)³⁵. Recently, however, new investigations featuring highly sensitive genetic tracing approaches^{43–46} found a much more restricted distribution of TRPV1 markers limited chiefly to primary afferent neurons in the spinal cord DRG, the cranial nerve cervical ganglia, and the trigeminal ganglia. The highest density of TRPV1 expression included central primary afferent synaptic terminal fields. TRPV1 expression was limited to a few discrete brain regions, including near the caudal hypothalamus, but was absent in regions previously linked to TRPV1 pharmacologically such as the hippocampus⁴⁶. TRPV1 within primary afferents was limited largely to peptidergic, primary afferent neurons⁴³. Expression of TRPV1 is present throughout these neurons – peripheral sensory endings, axonally as well as the cell body and is not limited to specific locations within neurons such as proteins limited to synaptic regions or the spike initiation zone⁴⁰. However, we have only a limited understanding of the details of trafficking control. TRPV1 expression is increased during inflammation and the pro-inflammatory cytokine tumor necrosis factor- α promoted increased TRPV1 insertion into plasmalemma of cultured trigeminal primary afferent neurons in a process associated with co-expression of other synaptic proteins, including Munc18-1, syntaxin1, and SNAP-25⁴⁷. It remains uncertain whether this scheme is generalizable and especially whether it differs between somatosensory and visceral primary afferents.

TRPV1 in brainstem synaptic signaling

Craniovisceral primary afferent neurons (nodose, jugular, and petrosal) send axons centrally via the solitary tract (ST) to synapse predominantly within caudal portions of the NTS^{48,49}. Most ST afferents have unmyelinated axons which overwhelmingly are TRPV1⁺, whereas the faster-conducting A δ lack TRPV1⁵⁰. Despite such expression, endogenous TRPV1 activity is difficult to discern in a largely homeostatically controlled internal milieu. *In vivo* evidence of endogenous TRPV1 activation in cranial afferents is indirect and controversial^{30,32,51,52} and suggests that tonic TRPV1 activation of vagal afferents

contributes to thermoregulation. Similarly, the activation of TRPV1 on central sensory terminals seems unlikely given the high canonical threshold requirements². ST afferent transmission to second-order NTS neurons is relatively conventional with significant deviations from central glutamate transmission expectations. ST axons release glutamate to generate large excitatory postsynaptic currents (EPSCs) primarily through non-NMDA receptors as well as modulation via metabotropic glutamate receptors (mGluRs)^{53–55}. The base, uniformly high probability of glutamate release^{56–58} means that frequency-dependent depression dominates afferent transmission. Stimuli delivered to the visible ST activate tract axons generating all-or-nothing EPSCs consistent with unitary responses with high likelihood of triggering postsynaptic action potentials. Such ST-evoked transmission relies on the synchronous release of glutamate vesicles. ST input is most often limited to a single afferent, suggesting that convergence is quite limited⁵⁸ as observed *in vivo*⁵⁹. Remarkably, even when multiple ST inputs do converge on a single neuron, ST inputs either are TRPV1⁺ or lack TRPV1—a segregation of afferents by TRPV1 expression regardless of sensory modality^{60–62}.

Synaptic responses suggest that presynaptic glutamate release mechanisms within TRPV1⁺ ST terminals differ from TRPV1[–] terminals not by synchronous release⁵⁸ but by two additional modes of glutamate release. Rates of “spontaneous” EPSCs (that is, action potential-independent release) are 10-fold higher than TRPV1[–] afferents even in tetrodotoxin (TTX)^{63,64}. The second added mode of release is the appearance of “asynchronous” spontaneous EPSCs (sEPSCs) following bursts of ST stimuli. Asynchronous release was elevated for seconds following the cessation of ST-evoked release. With sustained high frequencies of ST activation, synchronous EPSC amplitudes declined to less than 15% of control, but paradoxically the asynchronous rate simultaneously rose nearly fourfold⁶⁴. Thus, the probability of evoked release declined while asynchronous release rose, indicating that separate mechanisms controlled distinct pools of glutamate vesicles⁶⁴. Synchronous and asynchronous release required calcium entry through voltage-activated calcium channels (VACCs), but sEPSCs were unaffected by block of N-type VACCs⁶⁵. Thus, two modes of glutamate release depended on VACC calcium entry but spontaneous release did not. ST transmission depended on multiple, non-overlapping pools of vesicles. But how was calcium being separated within these terminals and where was calcium for sEPSCs coming from?

TRPV1 expression was clearly limited to ST central terminals within the NTS and predicted elevated sEPSC rates^{46,66,67}. Capsaicin (50 to 100 nM) had two effects on ST transmission: it robustly increased “spontaneous” glutamate vesicle release (sEPSCs), but within 1 to 5 minutes of exposure, ST shocks fail to activate the synchronized vesicle release for evoked EPSCs despite the continued high rate of sEPSCs. This puzzling pairing of facilitating one release while inhibiting the other reflects the dual nature of TRPV1 activation: depolarization and calcium entry, respectively. ST-evoked transmission required intact excitability to convey the ST shocks and excitation from axon site to terminal. We attribute the blockade of ST-evoked release

during TRPV1 to sustained depolarizing inward currents remote from the terminals which inactivate voltage-dependent excitability as reflected in gradual increases in conduction time (ST-EPSC latency) preceding synaptic failure^{68–70}. Calcium entry via TRPV1 selectively increases sEPSC rate.

Neurotransmission depends most directly on calcium⁷¹. We anticipated that, since TRPV1 is highly calcium-selective, TRPV1 activation would augment glutamate release. Certainly, reducing external calcium concentration decreased the sEPSC rate⁷⁰, so calcium entry is required. In TTX, cadmium, a broad-spectrum VACC blocker, blocked evoked release without altering sEPSCs in TRPV1⁺ neurons—findings that collectively indicate that VACCs do not contribute to spontaneous release of glutamate. However, for NTS neurons, lowering the bath temperature to room temperature reduced sEPSCs and raising the temperature elevated sEPSC rate only in TRPV1⁺ neurons but neurons with ST inputs lacking TRPV1 were unaffected by such temperatures^{63–65}. Thus, physiological temperatures were gating presynaptically expressed TRPV1 to allow calcium entry and produced a basal, stochastic vesicle release onto NTS second-order neurons. Vanilloid and temperature act cooperatively at ST TRPV1 to sensitize basal glutamate release⁶⁹. Temperature affected ST conduction times irrespective of TRPV1 expression but did not alter ST-EPSC amplitudes (that is, release)⁶⁹. Interestingly, this also indicated that TRPV1-related calcium influx into the synaptic terminals did not contribute to synchronous release. Together, the evidence suggested that TRPV1 controlled a distinct pool of glutamate vesicles that were not affected by action potentials. The independence of ST-EPSCs from TRPV1 activity may mean that the vesicles released by each stimulus are somehow effectively isolated from each other.

Multiple potential sources of calcium entry exist in ST terminals and include a diverse VACC family⁷² plus TRPV1 and serotonin 3 receptors (5-HT₃Rs)⁷¹. Logically, calcium entering ST terminals might mix to augment multiple forms of glutamate release. Already, augmented TRPV1 activity did not boost ST-evoked EPSCs as would be expected. We decided to introduce calcium buffers to intercept calcium entering via different calcium entry sources simultaneously^{73,74}. Our advantage with ST transmission is that we can assay multiple modes of synaptic release (evoked, spontaneous, and asynchronous) simultaneously within individual neurons. Depending on affinity and concentration, calcium buffers will intercept calcium diffusing from the entry pore to the vesicle so that differences in buffering magnitude and timing will reflect positioning of calcium source relative to released vesicles. The introduction of calcium buffer first reduced asynchronous EPSC rates, suggesting that asynchronous vesicle release required the greatest diffusion distances compared with synchronously released vesicles making up the evoked ST-EPSCs amplitudes⁶⁵. Interestingly, sEPSCs or thermal responses were unaltered by buffering, suggesting a close association of TRPV1 with its vesicles within a nanodomain. Buffering therefore distinguishes asynchronous vesicles as possessing a highly sensitive calcium sensor located perhaps more distant from VACCs than synchronous vesicles. Taken as a whole, our findings suggest distinct mechanisms of release for synchronous, asynchronous, and

spontaneous vesicles that are likely to reside in unique, spatially separated vesicle domains. Collectively, these studies support a critical topology within the terminal that isolates a TRPV1 mechanism of release separate from a VACC release mechanism⁷¹. Such a nanostructuring of the synaptic terminals offers a scaffold for differential release, modulation, and integration.

Modulation of release modules

G protein-coupled receptors (GPCRs) encompass a wide swath of signaling molecules and a substantial genomic proportion^{75,76}. NTS and specifically the presynaptic afferent terminals are richly endowed with more than a score of different GPCRs often devoted to peptides^{48,49}. Given the distinct release patterns centered on calcium entry sources and release modules, ST-NTS transmission offers diverse examples of both highly focused and broad-based GPCR targeting. Perhaps the most discrete example to date is CB1. The majority of ST inputs expressed CB1 regardless of TRPV1 responsiveness. Activation of CB1 selectively inhibits evoked synchronous glutamate release without altering basal or thermally activated TRPV1-mediated release of glutamate⁷⁷. The bifunctional, endogenous arachidonate metabolite N-arachidonyldopamine (NADA) activated both CB1 and TRPV1 and appropriately inhibited evoked ST-EPSCs while augmenting sEPSCs with each effect blocked by highly selective, competitive antagonists targeted to either CB1 or TRPV1⁷⁷. Activation of vasopressin 1a receptors (V1aR), depressed both spontaneous and ST-evoked synchronous release of glutamate and independently blocked conduction into ST terminals⁵⁶. Activation of oxytocin receptors (OTRs) increased both spontaneous and ST-evoked synchronous release of glutamate⁵⁷. Thus, V1aR and OTR are expressed in small subsets of ST afferent terminals and likely represent highly discrete modulation of specific afferent pathways through NTS and beyond. Given the block of both spontaneous and evoked release, these GPCRs must be expressed at both release nanodomains controlling those subsets of vesicles. One of the most ubiquitous GPCRs in NTS is ST presynaptic gamma amino butyric acid type B receptor (GABA_BR). GABA_BRs depressed all forms of glutamate release in NTS: synchronous, asynchronous, and spontaneous, including thermal gating of TRPV1⁷⁸. We speculate that the patterns suggest that GPCRs will be localized within specific release module nanodomains within ST terminals. The implication is that highly discrete modulation relies on physical distribution whereas broad GPCR modulation reflects multiple placements of GPCRs within or across signaling domains. Surprising genetic-proteomic evidence suggests that, in some peripheral somatic sensory neurons, GABA_BR 1 subunits are positioned with TRPV1 and can switch the sensitized state of TRPV1 and this non-canonical, direct coupled mechanism requires a critical proximity⁷⁹. Suffice it to say, the nanoscale landscape regarding TRPV1 will require improved tools and more refined spatially discrete approaches to verify the key aspects of nanoscale signaling and appropriate trafficking to support such mechanisms.

Out-of-canon TRPV1

The experimental results in NTS and brainstem to date are importantly discrepant with multiple canonical assumptions.

First and foremost, the basal thermal threshold for TRPV1 lies in the mid-range of physiological temperatures existing at the expression site. *In vivo*, introduction of capsazepine alone systemically or into NTS had no effect on respiration, blood pressure, or heart rate^{80,81}. Although temperature is set at artificially low temperatures for slice recordings, the sEPSC rates average over 20 Hz at normal brain temperatures and generate substantial autonomous action potential firing without ST stimulation^{63,64}. Clearly, such autonomous firing and the signals arriving at distant projection sites could be modulated by GPCRs without the necessity for peripheral afferent activity. The sustained activation of ST TRPV1 by vanilloids or temperature suggests that vesicle depletion or desensitization is moderate to none over extended time frames^{64,69}. Vanilloid competitive antagonists are effective in blocking agonist (capsaicin or RTX) responses at ST TRPV1 but not other modes of TRPV1 activation, including heat in NTS⁶⁹, in contrast to capsazepine block of heat responses in transfected HEK293 cells⁴⁰. Externally applied QX-314 has attracted considerable attention in blocking nociception when coupled to TRPV1 activation in somatosensory neurons^{82,83}, but QX-314 non-selectively blocks ST-NTS transmission regardless of TRPV1 expression⁶⁸. Collectively, such contrasting results raise the question of whether somatosensory TRPV1 is fundamentally different from craniovisceral TRPV1. Developmentally, DRG and nodose neurons derive from neural crest and placode cells, respectively, and these embryological origins are associated with a number of distinctions regarding ion channel, GPCR, and neurotransmitter expression^{84–86}. Although the origins of these functional differences remain unclear, the evidence of differences is substantial.

Endogenous activation

The origin of the sensitized or physiological range of thermal sensitivity of cranial visceral TRPV1 afferents is unclear. In ST afferents, sEPSC release is insensitive to competitive vanilloid antagonists, suggesting that, *in vitro*, an endogenous agonist

(for example, inflammatory mediator) is not responsible⁶⁹. Suggested endogenous ligands for TRPV1 include anandamide and other bioactive lipids like lysophosphatidic acid⁸⁷, but functional cases are limited⁸⁸. Oleoylethanolamide (OEA) is an endogenous fatty acid ethanolamine that is produced in the intestinal mucosa in the fed state. High concentrations of OEA activate vagal afferents⁸⁹, but it is unclear whether endogenous levels are sufficient. Oleic acid inhibits DRG TRPV1⁹⁰, as does anandamide⁹¹, but neither is effective in ST TRPV1⁹² (unpublished results). Thus, the role of endogenous lipid metabolites in TRPV1 activation or sensitization remains largely unresolved.

Future directions

TRPV1 is long recognized as an impactful physiological and pathophysiological molecule. The bluntness and imprecision of many of the available tools have been remarkably frustrating. Drug development has been stymied by targeted purpose programs that were stopped by unintended TRPV1 actions off target. Clearly, newer and perhaps more discrete approaches and tools might be helpful in all respects. The complicated fate of membrane lipid metabolites and their spatial control make the pursuit of endogenous TRPV1 actors daunting. Biology-informed synthetic chemistry may hold promise²². For example, synthesis of appropriately spatially constrained, photoactivated tools might offer better insights into discrete localization of TRPV1 in appropriate biological models⁹³.

Abbreviations

DRG, dorsal root ganglia; EPSC, excitatory postsynaptic current; GABA_BR, gamma amino butyric acid type B receptor; GPCR, G protein-coupled receptor; NTS, nucleus of the solitary tract; OEA, oleoylethanolamide; OTR, oxytocin receptor; RTX, resiniferatoxin; sEPSC, spontaneous excitatory postsynaptic current; ST, solitary tract; TRPV1, transient receptor potential vanilloid 1; TTX, tetrodotoxin; V1aR, vasopressin 1a receptor; VACC, voltage-activated calcium channel

References

- Caterina MJ, Schumacher MA, Tominaga M, *et al.*: **The capsaicin receptor: a heat-activated ion channel in the pain pathway.** *Nature*. 1997; **389**(6653): 816–24. [PubMed Abstract](#) | [Publisher Full Text](#)
- Julius D: **TRP channels and pain.** *Annu Rev Cell Dev Biol*. 2013; **29**: 355–84. [PubMed Abstract](#) | [Publisher Full Text](#)
- Fitzgerald M: **Capsaicin and sensory neurones—a review.** *Pain*. 1983; **15**(2): 109–30. [PubMed Abstract](#) | [Publisher Full Text](#)
- Buck SH, Burks TF: **The neuropharmacology of capsaicin: review of some recent observations.** *Pharmacol Rev*. 1986; **38**(3): 179–226. [PubMed Abstract](#)
- Chiou KL, Hastorf CA, Bonavia D, *et al.*: **Documenting Cultural Selection Pressure Changes on Chile Pepper (*Capsicum baccatum* L.) Seed Size Through Time in Coastal Peru (7,600 B.P.–Present).** *Econ Bot*. 2014; **68**: 190–202. [Publisher Full Text](#)
- Julius D, Basbaum AI: **Molecular mechanisms of nociception.** *Nature*. 2001; **413**: 203–10. [PubMed Abstract](#) | [Publisher Full Text](#)
- Grandl J, Kim SE, Uzzell V, *et al.*: **Temperature-induced opening of TRPV1 ion channel is stabilized by the pore domain.** *Nat Neurosci*. 2010; **13**(6): 708–14. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kuzhikandathil EV, Wang H, Szabo T, *et al.*: **Functional analysis of capsaicin receptor (vanilloid receptor subtype 1) multimerization and agonist responsiveness using a dominant negative mutation.** *J Neurosci*. 2001; **21**(22): 8697–706. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gao Y, Cao E, Julius D, *et al.*: **TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action.** *Nature*. 2016; **534**: 347–51. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Cao E, Liao M, Cheng Y, *et al.*: **TRPV1 structures in distinct conformations reveal activation mechanisms.** *Nature*. 2013; **504**(7478): 113–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Tominaga M, Tominaga T: **Structure and function of TRPV1.** *PLoS Arch*. 2005; **451**(1): 143–50. [PubMed Abstract](#) | [Publisher Full Text](#)
- López-Romero AE, Hernández-Araiza I, Torres-Quiroz F, *et al.*: **TRP ion channels: Proteins with conformational flexibility.** *Channels (Austin)*. 2019;

- 13(1): 207–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
13. **F** Kaszas K, Keller JM, Coddou C, *et al.*: Small molecule positive allosteric modulation of TRPV1 activation by vanilloids and acidic pH. *J Pharmacol Exp Ther.* 2012; **340**(1): 152–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 14. Caterina MJ, Julius D: The vanilloid receptor: a molecular gateway to the pain pathway. *Annu Rev Neurosci.* 2001; **24**: 487–517.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. **F** Chung MK, Güler AD, Caterina MJ: TRPV1 shows dynamic ionic selectivity during agonist stimulation. *Nat Neurosci.* 2008; **11**(5): 555–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 16. Premkumar LS, Abooj M: TRP channels and analgesia. *Life Sci.* 2013; **92**(8–9): 415–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 17. Matta JA, Ahern GP: TRPV1 and synaptic transmission. *Curr Pharm Biotechnol.* 2011; **12**(1): 95–101.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. van der Stelt M, Di Marzo V: Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. *Eur J Biochem.* 2004; **271**(10): 1827–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Ross RA: Anandamide and vanilloid TRPV1 receptors. *Br J Pharmacol.* 2003; **140**(5): 790–801.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Di Marzo V, Bisogno T, de Petrocellis L: Anandamide: some like it hot. *Trends Pharmacol Sci.* 2001; **22**(7): 346–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Sharkey KA, Wiley JW: The Role of the Endocannabinoid System in the Brain-Gut Axis. *Gastroenterology.* 2016; **151**(2): 252–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Blankman JL, Cravatt BF: Chemical probes of endocannabinoid metabolism. *Pharmacol Rev.* 2013; **65**(2): 849–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. **F** Maccarrone M: Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years. *Front Mol Neurosci.* 2017; **10**: 166.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 24. Koplas PA, Rosenberg RL, Oxford GS: The role of calcium in the desensitization of capsaicin responses in rat dorsal root ganglion neurons. *J Neurosci.* 1997; **17**(10): 3525–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Rosenbaum T, Gordon-Shaag A, Munari M, *et al.*: Ca²⁺/calmodulin modulates TRPV1 activation by capsaicin. *J Gen Physiol.* 2004; **123**(1): 53–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Sanz-Salvador L, Andrés-Borderia A, Ferrer-Montiel A, *et al.*: Agonist- and Ca²⁺-dependent desensitization of TRPV1 channel targets the receptor to lysosomes for degradation. *J Biol Chem.* 2012; **287**(23): 19462–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Berthoud HR, Patterson LM, Willing AE, *et al.*: Capsaicin-resistant vagal afferent fibers in the rat gastrointestinal tract: Anatomical identification and functional integrity. *Brain Res.* 1997; **746**(1–2): 195–206.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. **F** Brown DC, Agnello K, Iadarola MJ: Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain. *Pain.* 2015; **156**(6): 1018–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 29. **F** Sapio MR, Neubert JK, LaPaglia DM, *et al.*: Pain control through selective chemo-ablation of centrally projecting TRPV1⁺ sensory neurons. *J Clin Invest.* 2018; **128**(4): 1657–1670.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 30. **F** Wong GY, Gavva NR: Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. *Brain Res Rev.* 2009; **60**(1): 267–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 31. **F** Gavva NR, Bannon AW, Surapaneni S, *et al.*: The Vanilloid Receptor TRPV1 Is Tonically Activated *In Vivo* and Involved in Body Temperature Regulation. *J Neurosci.* 2007; **27**(13): 3366–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 32. Romanovsky AA, Almeida MC, Garami A, *et al.*: The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. *Pharmacol Rev.* 2009; **61**(3): 228–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Blackshaw LA, Page AJ, Partosoedarmo ER: Acute effects of capsaicin on gastrointestinal vagal afferents. *Neuroscience.* 2000; **96**(2): 407–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Patterson LM, Zheng H, Ward SM, *et al.*: Vanilloid receptor (VR1) expression in vagal afferent neurons innervating the gastrointestinal tract. *Cell Tissue Res.* 2003; **311**(3): 277–87.
[PubMed Abstract](#)
 35. Roberts JC, Davis JB, Benham CD: [³H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. *Brain Res.* 2004; **995**(2): 176–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Ni D, Gu Q, Hu HZ, *et al.*: Thermal sensitivity of isolated vagal pulmonary sensory neurons: Role of transient receptor potential vanilloid receptors. *Am J Physiol Regul Integr Comp Physiol.* 2006; **291**(3): R541–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Coleridge JC, Coleridge HM: Afferent vagal C fibre innervation of the lungs and airways and its functional significance. *Rev Physiol Biochem Pharmacol.* 1984; **99**: 1–110.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Szolcsanyi J: Actions of capsaicin on sensory receptors. In Wood J, editor. *Capsaicin in the Study of Pain.* London: Academic Press; 1993; 1–26.
[Reference Source](#)
 39. Hori T: Capsaicin and central control of thermoregulation. *Pharmacol Ther.* 1984; **26**(3): 389–416.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Tominaga M, Caterina MJ, Malmberg AB, *et al.*: The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli. *Neuron.* 1998; **21**(3): 531–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Randich A, Ren K, Gebhart GF: Electrical stimulation of cervical vagal afferents. II. Central relays for behavioral antinociception and arterial blood pressure decreases. *J Neurophysiol.* 1990; **64**(4): 1115–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Ren K, Randich A, Gebhart GF: Vagal afferent modulation of spinal nociceptive transmission in the rat. *J Neurophysiol.* 1989; **62**(2): 401–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Cavanaugh DJ, Chesler AT, Bráz JM, *et al.*: Restriction of transient receptor potential vanilloid-1 to the peptidergic subset of primary afferent neurons follows its developmental downregulation in nonpeptidergic neurons. *J Neurosci.* 2011; **31**(28): 10119–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. **F** Cavanaugh DJ, Lee H, Lo L, *et al.*: Distinct subsets of unmyelinated primary sensory fibers mediate behavioral responses to noxious thermal and mechanical stimuli. *Proc Natl Acad Sci U S A.* 2009; **106**(22): 9075–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 45. Zhang J, Cavanaugh DJ, Nemenov MI, *et al.*: The modality-specific contribution of peptidergic and non-peptidergic nociceptors is manifest at the level of dorsal horn nociceptive neurons. *J Physiol.* 2013; **591**(4): 1097–110.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. **F** Cavanaugh DJ, Chesler AT, Jackson AC, *et al.*: Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. *J Neurosci.* 2011; **31**(13): 5067–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 47. **F** Meng J, Wang J, Steinhoff M, *et al.*: TNF α induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion. *Sci Rep.* 2016; **6**: 21226.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 48. Andresen MC, Paton JF: The nucleus of the solitary tract: Processing information from viscerosensory afferents. In: Llewellyn-Smith IJ, Verberne AJ, editors. *Central Regulation of Autonomic Functions.* 2 ed. London: Oxford. 2011; 23–46.
[Publisher Full Text](#)
 49. Andresen MC, Kunze DL: Nucleus tractus solitarius--gateway to neural circulatory control. *Annu Rev Physiol.* 1994; **56**: 93–116.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Jin YH, Bailey TW, Li BY, *et al.*: Purinergic and vanilloid receptor activation releases glutamate from separate cranial afferent terminals in nucleus tractus solitarius. *J Neurosci.* 2004; **24**(20): 4709–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. **F** Chang RB: Body thermal responses and the vagus nerve. *Neurosci Lett.* 2019; **698**: 209–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 52. **F** Steiner AA, Turek VF, Almeida MC, *et al.*: Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. *J Neurosci.* 2007; **27**(28): 7459–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 53. Fernandes LG, Jin YH, Andresen MC: Heterosynaptic crosstalk: GABA-glutamate metabotropic receptors interactively control glutamate release in solitary tract nucleus. *Neuroscience.* 2011; **174**: 1–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Jin YH, Bailey TW, Andresen MC: Cranial afferent glutamate heterosynaptically modulates GABA release onto second-order neurons via distinctly segregated metabotropic glutamate receptors. *J Neurosci.* 2004; **24**(42): 9332–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Andresen MC, Yang MY: Non-NMDA receptors mediate sensory afferent synaptic transmission in medial nucleus tractus solitarius. *Am J Physiol.* 1990; **259**(4 pt 2): H1307–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Bailey TW, Jin YH, Doyle MW, *et al.*: Vasopressin Inhibits Glutamate Release

- via Two Distinct Modes in the Brainstem. *J Neurosci.* 2006; 26(23): 6131–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Peters JH, McDougall SJ, Kellett DO, *et al.*: Oxytocin Enhances Cranial Visceral Afferent Synaptic Transmission to the Solitary Tract Nucleus. *J Neurosci.* 2008; 28(45): 11731–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Andresen MC, Peters JH: Comparison of baroreceptive to other afferent synaptic transmission to the medial solitary tract nucleus. *Am J Physiol Heart Circ Physiol.* 2008; 295(5): H2032–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Mifflin SW: Convergent carotid sinus nerve and superior laryngeal nerve afferent inputs to neurons in the NTS. *Am J Physiol.* 1996; 271(4 Pt 2): R870–R880.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. McDougall SJ, Andresen MC: Viscerosensory signal integration at amygdala-projecting NTS neurons. [FASEB Summer Conference Meeting Abstract]. In press 2013.
 61. Andresen MC, Hofmann ME, Fawley JA: The unsilent majority-TRPV1 drives “spontaneous” transmission of unmyelinated primary afferents within cardiorespiratory NTS. *Am J Physiol Regul Integr Comp Physiol.* 2012; 303(12): R1207–R1216.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Peters JH, McDougall SJ, Fawley JA, *et al.*: TRPV1 marks synaptic segregation of multiple convergent afferents at the rat medial solitary tract nucleus. *PLoS One.* 2011; 6(9): e25015.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. Shoudai K, Peters JH, McDougall SJ, *et al.*: Thermally active TRPV1 tonically drives central spontaneous glutamate release. *J Neurosci.* 2010; 30(43): 14470–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. Peters JH, McDougall SJ, Fawley JA, *et al.*: Primary afferent activation of thermosensitive TRPV1 triggers asynchronous glutamate release at central neurons. *Neuron.* 2010; 65(5): 657–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Fawley JA, Hofmann ME, Andresen MC: Distinct Calcium Sources Support Multiple Modes of Synaptic Release from Cranial Sensory Afferents. *J Neurosci.* 2016; 36(34): 8957–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. Guo A, Vulchanova L, Wang J, *et al.*: Immunocytochemical localization of the vanilloid receptor 1 (VR1): Relationship to neuropeptides, the P2X₃ purinoceptor and IB4 binding sites. *Eu J Neurosci.* 1999; 11(3): 946–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Ritter S, Dinh TT: Capsaicin-induced neuronal degeneration: silver impregnation of cell bodies, axons, and terminals in the central nervous system of the adult rat. *J Comp Neurol.* 1988; 271(1): 79–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Hofmann ME, Largent-Milnes TM, Fawley JA, *et al.*: External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1. *J Neurophysiol.* 2014; 112(11): 2697–706.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. Hofmann ME, Andresen MC: Vanilloids selectively sensitize thermal glutamate release from TRPV1 expressing solitary tract afferents. *Neuropharmacology.* 2016; 101: 401–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 70. Fawley JA, Doyle MW, Andresen MC: 5-HT₃R-sourced calcium enhances glutamate release from a distinct vesicle pool. *Brain Res.* 2019; 1721: 146346.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 71. Fawley JA, Andresen MC: Distinct Calcium Sources Define Compartmentalized Synaptic Signaling Domains. *Neuroscientist.* 2019; 25(5): 408–419.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Mendelowitz D, Reynolds PJ, Andresen MC: Heterogeneous functional expression of calcium channels at sensory and synaptic regions in nodose neurons. *J Neurophysiol.* 1995; 73(2): 872–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Courtney NA, Briguglio JS, Bradberry MM, *et al.*: Excitatory and Inhibitory Neurons Utilize Different Ca²⁺ Sensors and Sources to Regulate Spontaneous Release. *Neuron.* 2018; 98(5): 977–991.e5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Graydon CW, Cho S, Li GL, *et al.*: Sharp Ca²⁺ nanodomains beneath the ribbon promote highly synchronous multivesicular release at hair cell synapses. *J Neurosci.* 2011; 31(46): 16637–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 75. Gerber KJ, Squires KE, Hepler JR: Roles for Regulator of G Protein Signaling Proteins in Synaptic Signaling and Plasticity. *Mol Pharmacol.* 2016; 89(2): 273–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. Roth BL, Kroeze WK: Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily. *J Biol Chem.* 2015; 290(32): 19471–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Fawley JA, Hofmann ME, Andresen MC: Cannabinoid 1 and transient receptor potential vanilloid 1 receptors discretely modulate evoked glutamate separately from spontaneous glutamate transmission. *J Neurosci.* 2014; 34(24): 8324–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 78. Fawley JA, Peters JH, Andresen MC: GABA_A-mediated inhibition of multiple modes of glutamate release in the nucleus of the solitary tract. *J Neurophysiol.* 2011; 106(4): 1833–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. Hanack C, Moroni M, Lima WC, *et al.*: GABA blocks pathological but not acute TRPV1 pain signals. *Cell.* 2015; 160(4): 759–770.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. Mazzone SB, Geraghty DP: Respiratory action of capsaicin microinjected into the nucleus of the solitary tract: involvement of vanilloid and tachykinin receptors. *Br J Pharmacol.* 1999; 127(2): 473–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 81. Malinowska B, Kwolek G, Göthert M: Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. *Naunyn Schmiedeberg Arch Pharmacol.* 2001; 364(6): 562–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Binshtok AM, Gerner P, Oh SB, *et al.*: Coapplication of lidocaine and the permanently charged sodium channel blocker QX-314 produces a long-lasting nociceptive blockade in rodents. *Anesthesiology.* 2009; 111(1): 127–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 83. Puopolo M, Binshtok AM, Yao GL, *et al.*: Permeation and block of TRPV1 channels by the cationic lidocaine derivative QX-314. *J Neurophysiol.* 2013; 109(7): 1704–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Mazzone SB, Udem BJ: Vagal Afferent Innervation of the Airways in Health and Disease. *Physiol Rev.* 2016; 96(3): 975–1024.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. Zhuo H, Ichikawa H, Helke CJ: Neurochemistry of the nodose ganglion. *Prog Neurobiol.* 1997; 52(2): 79–107.
[PubMed Abstract](#) | [Publisher Full Text](#)
 86. Kollarik M, Ru F, Udem BJ: Phenotypic distinctions between the nodose and jugular TRPV1-positive vagal sensory neurons in the cynomolgus monkey. *Neuroreport.* 2019; 30(8): 533–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 87. Nieto-Posadas A, Picazo-Juárez G, Llorente I, *et al.*: Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site. *Nat Chem Biol.* 2011; 8(1): 78–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Di Marzo V, de Petrocellis L: Why do cannabinoid receptors have more than one endogenous ligand? *Phil Trans R Soc B Biol Sci.* 2012; 367(1607): 3216–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 89. Wang X, Miyares RL, Ahern GP: Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. *J Physiol.* 2005; 564(Pt 2): 541–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 90. Morales-Lázaro SL, Llorente I, Sierra-Ramírez F, *et al.*: Inhibition of TRPV1 channels by a naturally occurring omega-9 fatty acid reduces pain and itch. *Nat Commun.* 2016; 7: 13092.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 91. Tognetto M, Amadesi S, Harrison S, *et al.*: Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. *J Neurosci.* 2001; 21(4): 1104–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 92. Fenwick AJ, Fowler DK, Wu SW, *et al.*: Direct Anandamide Activation of TRPV1 Produces Divergent Calcium and Current Responses. *Front Mol Neurosci.* 2017; 10: 200.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 93. Frank JA, Moroni M, Moshourab R, *et al.*: Photoswitchable fatty acids enable optical control of TRPV1. *Nat Commun.* 2015; 6: 7118.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Andrei V Derbenev**
Department of Physiology, School of Medicine, Tulane University, New Orleans, Louisiana, USA
Competing Interests: No competing interests were disclosed.
2. **Renato Alberto Travagli**
Department of Neural and Behavioral Sciences, Penn State - College of Medicine, Hershey, PA, USA
Competing Interests: No competing interests were disclosed.
3. **Tamara Rosenbaum**
Departamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Coyoacan, México City, Mexico
Competing Interests: No competing interests were disclosed.
4. **David D Kline**
Department of Biomedical Sciences, Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research